Dear Doctor… Regarding Calcium Channel Blockers

JAMA: The Journal of the American Medical Association

Volumn 275, Issue 7, 1996, Pages 517-518

  Stryer, Daniel B ^a   Lurie, Peter ^b   Bero, Lisa A ^c  

^a Kayenta Health Center   (United States)

^b Public Citizen Health Research Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; RESERPINE;

CLINICAL FEATURE; CORONARY RISK; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; LETTER; MEDICAL ETHICS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 13344250501     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1996.03530310023018     Document Type: Letter

References (6)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
2. Prescription drug advertising. Code of Federal Regulations. 1981;21(pt 201 and 202):55-64.
3. Adams DG. FDA regulation of promotion of drugs: a legal primer. Drug Info J. 1989;23:625-633.
4. Responsibility for nifedipine letter debated. Washington Drug Lett. September 25, 1995:1-2.
5. Rennie D, Flanagin A, Glass RM. Conflict of interest in the publication of science. JAMA. 1991;266:266-267.
6. Draft policy statement on industry-supported scientific and educational activities. Federal Register. November 27, 1992;57:56412-56414.